TY - JOUR T1 - Gut microbiota alterations in patients with persistent respiratory dysfunction three months after severe COVID-19 JF - medRxiv DO - 10.1101/2021.07.13.21260412 SP - 2021.07.13.21260412 AU - Beate Vestad AU - Thor Ueland AU - Tøri Vigeland Lerum AU - Tuva Børresdatter Dahl AU - Kristian Holm AU - Andreas Barratt-Due AU - Trine Kåsine AU - Anne Ma Dyrhol-Riise AU - Birgitte Stiksrud AU - Kristian Tonby AU - Hedda Hoel AU - Inge Christoffer Olsen AU - Katerina Nezvalova Henriksen AU - Anders Tveita AU - Ravinea Manotheepan AU - Mette Haugli AU - Ragnhild Eiken AU - Åse Berg AU - Bente Halvorsen AU - Tove Lekva AU - Trine Ranheim AU - Annika Elisabeth Michelsen AU - Anders Benjamin Kildal AU - Asgeir Johannessen AU - Lars Thoresen AU - Hilde Skudal AU - Bård Reiakvam Kittang AU - Roy Bjørkholt Olsen AU - Carl Magnus Ystrøm AU - Nina Vibeche Skei AU - Raisa Hannula AU - Saad Aballi AU - Reidar Kvåle AU - Ole Henning Skjønsberg AU - Pål Aukrust AU - Johannes Roksund Hov AU - Marius Trøseid AU - on behalf of the NOR-Solidarity study group Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/16/2021.07.13.21260412.abstract N2 - Objective Although COVID-19 is primarily a respiratory infection, mounting evidence suggests that the GI tract is involved in the disease, with gut barrier dysfunction and gut microbiota alterations being related to disease severity. Whether these alterations persist and could be related to long-term respiratory dysfunction is unknown.Design From the NOR-Solidarity trial (n=181), plasma was collected during hospital admission and after three months, and analyzed for markers of gut barrier dysfunction and inflammation. At the three-month follow-up, pulmonary function was assessed by measuring diffusing capacity of the lungs for carbon monoxide (DLCO), and rectal swabs for gut microbiota analyses were collected (n= 97) and analysed by sequencing of the 16S rRNA gene.Results Gut microbiota diversity was reduced in COVID-19 patients with persistent respiratory dysfunction, defined as DLCO below lower limit of normal three months after hospitalization. These patients also had an altered global gut microbiota composition, with reduced abundance of Erysipelotrichaceae UCG-003 and increased abundance of Flavonifractor and Veillonella, the latter potentially being linked to fibrosis. During hospitalization, increased plasma levels of lipopolysaccharide-binding protein (LBP) were strongly associated with respiratory failure, defined as pO2/fiO2-(P/F-ratio)<26.6 kPa. LBP levels remained elevated during and after hospitalization, and was associated with low-grade inflammation and persistent respiratory dysfunction after three months.Conclusion Persistent respiratory dysfunction after COVID-19 is associated with reduced biodiversity and gut microbiota alterations, along with persistently elevated LBP levels. Our results point to a potential gut-lung axis that should be further investigated in relation to long-term pulmonary dysfunction and long COVID.What is already known about this subject?Mounting evidence suggests that the gastrointestinal tract is involved in the pathogenesis of COVID-19, with the putative SARS-CoV-2 receptor ACE 2 ubiquitously expressed in the gut.In severe COVID-19, the gut-blood barrier is compromised, and leakage of microbial products, such as lipopolysaccharides (LPS), could affect the host’s response to COVID-19 infection.COVID-19 patients exhibit an altered gut microbiota composition, which has been related to disease severity. However, it is currently not known whether dysbiosis or gut barrier dysfunction persist long-term after hospitalization, or whether microbiota-related mechanisms could be related to persistent pulmonary dysfunction.What are the new findings?COVID-19 patients with persistent respiratory dysfunction after three months had a lower microbial diversity and an altered gut microbiota composition at the same time point.The microbiota alterations included reduced abundance of Erysipelotrichaceae UCG-003 and increased abundance of Veillonella and Flavonifractor.During hospitalization, increased plasma levels of LBP were strongly associated with respiratory failure.LBP levels remained elevated during and after hospitalization, and associated significantly with persistent respiratory dysfunction at three-month follow-up.How might it impact on clinical practice in the foreseeable future?Our findings point to a potential gut-lung axis in relation not only to respiratory failure during hospitalization, but also to long-term COVID-19 morbidity. Further studies on gut microbiota composition and gut barrier dysfunction as potential treatment targets and/or disease severity biomarkers in relation to long-term pulmonary dysfunction and long COVID are warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04321616Funding StatementThe study was funded by the National Clinical Therapy Research in the Specialist Health Services (KLINBEFORSK), Norway and South-Eastern Norway Regional Health Authority (grant number 2021071). The microbiota analyses were funded by the strategic research area Personalized microbiota therapy in clinical medicine (Oslo University Hospital). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Committee for Medical Research Ethics Region South East Norway (118684) and by the Norwegian Medicines Agency (20/04950-23).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the present study are available from the corresponding author on reasonable request. ER -